Medically reviewed by Uzm. Dr. Cihan BolatLast reviewed
"What is the success rate of stem cell therapy?" is the question we hear most often after "how much does it cost?" — and the honest answer is more nuanced than a single percentage. Success means different things to a patient with knee osteoarthritis (pain and function over 6–12 months), a family in an autism program (sleep, eye contact, language, behaviour), or a person living with multiple sclerosis (relapse activity, fatigue, MRI stability). At Istanbul Stem Cells, we discuss outcomes the way our medical team actually thinks about them: as ranges, against baseline, over a defined follow-up window.
Outcome ranges below summarise published clinical observations for mesenchymal stem cell (MSC) and exosome therapy in each indication, alongside our own structured follow-up at 1, 3 and 6 months. They are an honest planning reference, not a guarantee — individual response depends on diagnosis, severity, biology, biomechanics, medication and adherence to the post-procedure plan.
Outcome ranges
Reported outcome ranges by program.
The ranges below reflect the proportion of patients who report meaningful improvement against their pre-treatment baseline over the standard follow-up window. They are not cure rates — they describe measurable response, not disease eradication.
| Program | Reported meaningful response | What we measure |
|---|---|---|
| Knee osteoarthritis (mild–moderate) | 60–80% at 6–12 months | WOMAC / VAS pain, stiffness, function; activity level; reduced analgesic use |
| Tendon & sports injury | 65–80% at 3–6 months | Return-to-activity time; pain on load; ultrasound where appropriate |
| Multiple sclerosis (supportive) | 40–60% report improvement in fatigue / function at 6 months | EDSS context, fatigue scales, MRI activity (specialist-reviewed) |
| Peripheral neuropathy | 50–70% at 3–6 months | Pain scores, sensory testing, sleep, daily function |
| Autism spectrum (paediatric) | 50–70% of families report measurable change at 3–6 months | Parent-reported sleep, eye contact, language, behaviour; CARS context |
| Autoimmune & inflammatory | 40–60% report symptomatic improvement at 6 months | Symptom diaries, inflammatory markers, specialist co-review |
| Rejuvenation & recovery | Most patients report energy / recovery gains within 4–12 weeks | Energy, sleep, recovery, skin quality (patient-reported) |
Ranges synthesise published MSC and exosome clinical literature with our internal follow-up. Individual response varies. We discuss realistic, condition-specific expectations openly during your free consultation before any program is confirmed.
What "success rate" actually means in regenerative medicine.
Conventional drug trials measure success against a hard endpoint — a tumour shrinks, a virus clears. Regenerative medicine rarely works that way. Stem cell therapy and exosome therapy work biologically: they signal, modulate inflammation, and support repair over weeks and months. So "success" in our world is a measured improvement against your own pre-treatment baseline — not a cure, and not a one-size-fits-all percentage.
When you read a clinic advertising a "95% success rate" for stem cell therapy, treat it with caution. No reputable regenerative practice — including ours — quotes a single number, because the honest answer always depends on what was measured, in whom, and over what period.
Stem cell therapy success rate for knees.
Stem cell therapy for knees is the indication with the strongest published outcome data. For mild-to-moderate knee osteoarthritis treated with intra-articular MSC and/or exosome support, 60–80% of patients report meaningful improvement in pain and function at 6–12 months. Response is strongest in earlier-grade OA (KL grade 2–3), patients with healthy biomechanics, and those who follow a structured post-procedure rehab plan.
Patients with advanced structural damage (KL grade 4, bone-on-bone) typically see less benefit, and surgical consultation may remain the right first step. We tell you honestly which group your imaging places you in. See our cost page for the price range of orthopedic programs.
Outcomes in MS, neuropathy and neurological programs.
Neurological programs — particularly multiple sclerosis, Parkinson's, peripheral neuropathy and post-stroke recovery — are inherently more variable than orthopedics. Disease modification cannot be promised. What we plan around, and measure, is symptomatic and functional response: fatigue, mobility, neuropathic pain, sleep, autonomic function, and (in MS) MRI activity reviewed by your specialist.
Published observations and our own follow-up suggest 40–60% of MS patients and 50–70% of neuropathy patients report meaningful symptomatic improvement at 6 months. Patient selection matters — we are explicit about who is and is not a likely responder during clinical review.
Outcomes in our autism stem cell program.
Our stem cell therapy for autism program is parent-led at the measurement layer: parents are the most reliable observers of sleep, eye contact, language, behaviour and stimming over weeks and months. Roughly 50–70% of families report measurable change at 3–6 months following a multi-day program. We use parent-reported diaries alongside CARS context to evaluate response.
Change is rarely linear. We never present autism stem cell therapy as a cure, and we coordinate with your child's existing developmental and medical team throughout follow-up.
How we actually measure response after your program.
Every program at Istanbul Stem Cells includes structured follow-up at 1, 3 and 6 months by video or messaging in your preferred language. We capture condition-specific outcome measures — WOMAC and VAS for orthopedic patients, fatigue and function scales for neurological patients, parent diaries for paediatric autism programs, symptom and inflammatory markers for autoimmune patients.
We share follow-up notes with your referring physician on request. If your program has not produced meaningful change by the 3- or 6-month review, we will say so honestly and discuss whether a different strategy is appropriate.
Factors that genuinely move success rates.
Five factors do the heavy lifting in real outcomes: diagnosis specificity and disease stage (earlier and milder disease responds better); cell source, freshness and dose (we use fresh, never-frozen MSC and clinically appropriate dosing); application route (intra-articular, intravenous, intrathecal, intranasal — chosen by indication); combination with exosome support when clinically appropriate; and post-procedure adherence — rehab, medication coordination, lifestyle factors.
Honest medicine, plainly stated.
If a regenerative pathway is not the right step for you, we will say so. Our reputation depends on careful, honest recommendations — not on filling schedules. Begin with a free consultation, or read more about our mesenchymal stem cell therapy and exosome therapy programs.